Socazolimab

DB18845InvestigationalProtein Based Therapies

Socazolimab is under investigation in clinical trial NCT04878016 (A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-pd-l1 Antibody) in Patients With ES-SCLC).

Mechanism: Pharmacologically active on Programmed cell death 1 ligand 1
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human programmed death-ligand 1) (human monoclonal zkab001 .gamma.1-chain), disulfide with human monoclonal zkab001 .lambda.-chain, dimer
Code names: ZKAB-001

Resolves to

Compound

UNII82P4S8Q3FBCAS2305043-30-3

Targets

Q9NZQ7CD274

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Socazolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account